triple combo

March 8, 2019March 26, 2019

Positive Data from VX-445 Triple Combo Regimen Prompt Vertex to Seek Regulatory Approval

News

Vertex Pharmaceuticals is planning to request regulatory approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) during the third and fourth quarters of 2019, ... Read more

October 30, 2018October 30, 2018

VX-445 Triple Combo Improves Lung Function in CF Patients with F508del Mutations, Phase 2 Trial Shows

cystic fibrosis, News

Adding the investigational therapy VX-445 to tezacaftor (VX-661) and Kalydeco (ivacaftor) led to a roughly 10 percent improvement in the lung function of cystic fibrosis (CF) patients with F508del mutations in the CFTR gene ... Read more

April 5, 2018April 5, 2018

FDA Gives Fast Track Status to Proteostasis’ Triple Combo Treatment for CF

cystic fibrosis, News

The U.S. Food and Drug Administration has granted Fast Track Designation to Proteostasis Therapeutics’ triple combo treatment program for cystic fibrosis. The program includes the company’s amplifier, corrector, and ... Read more

February 22, 2018March 1, 2018

Vertex Begins First Phase 3 Trial Testing CF Triple Combo Therapy VX-659, Tezacaftor and Kalydeco

cystic fibrosis, News

Vertex Pharmaceuticals launched the first Phase 3 clinical trial investigating the triple combination therapy of VX-659, tezacaftor (VX-661), and Kalydeco (ivacaftor) in cystic fibrosis (CF) patients with one F508del mutation and one minimal ... Read more

Pin It on Pinterest